Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intas Biopharmaceuticals Ltd.

Division of Intas Pharmaceuticals Ltd.

Latest From Intas Biopharmaceuticals Ltd.

BiocurePharm Looks Beyond North America Via Canada IPO

With a business model that sets it apart from other South Korean bioventures, BiocurePharm plans to set up manufacturing facilities in North America and worldwide with local partners, and is launching a Canadian IPO in a bid to transform into a truly multinational operation, its CEO says.

Biosimilars Financing

Asia Firms Tweak Strategy Amid Biosimilars ‘Stampede’

More biosimilar approvals for Asian firms in western markets, building on the success of major players like Celltrion and Samsung, and a shift away from local/regional development strategies, were some of the key trends in the sector highlighted at a recent roundtable in India.

BioPharmaceutical Asia Pacific

Celltrion Files First Rituximab Biosimilar In Europe

Following the launch of its biosimilar version of Remicade, South Korea’s Celltrion has applied for European approval of its second biosimilar candidate, rituximab, marking the first filing in Europe for a biosimilar of the CD20-targeted oncology antibody.

BioPharmaceutical South Korea

India’s Ranbaxy, EPIRUS Strike Licensing Deal For Biosimilar Of J&J’s Remicade

Ranbaxy is the latest company to plan a big entry into the biosimilars market. It has now entered into a deal with Boston-headquartered EPIRUS to commercialize rheumatoid arthritis blockbuster infliximab in India and selected markets.

BioPharmaceutical Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Intas Pharmaceuticals Ltd.
  • Senior Management
  • Contact Info
  • Intas Biopharmaceuticals Ltd.
    Phone: (91) 2717 660100
    Plot No. 423 / P / A/ GIDC, Sarkhej
    Bavla Highway
    Ahmedabad, Gujarat, 382 210